Credit Suisse Ag Rapt Therapeutics, Inc. Transaction History

Credit Suisse Ag

$101 Billion
Q1 2024

A detailed history of Credit Suisse Ag transactions in Rapt Therapeutics, Inc. stock. As of the latest transaction made, Credit Suisse Ag holds 37,459 shares of RAPT stock, worth $1.08 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

37,459

Previous 37,425 0.09%

Holding current value

$1.08 Million

Previous $930,000 63.87%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$6.87 - $26.45 $233 - $899	34 Added 0.09%	37,459 $336,000
Q4 2023 Feb 08, 2024	BUY	$11.28 - $25.46 $40,472 - $91,350	3,588 Added 10.6%	37,425 $930,000
Q3 2023 Nov 13, 2023	SELL	$16.34 - $24.66 $84,657 - $127,763	-5,181 Reduced 13.28%	33,837 $562,000
Q2 2023 Aug 11, 2023	BUY	$16.06 - $21.61 $12,382 - $16,661	771 Added 2.02%	39,018 $729,000
Q1 2023 May 10, 2023	BUY	$17.19 - $30.8 $81,961 - $146,854	4,768 Added 14.24%	38,247 $701,000

Q4 2022 Feb 13, 2023	BUY	$16.28 - $24.6 $230,850 - $348,828	14,180 Added 73.48%	33,479 $662,000
Q3 2022 Nov 10, 2022	BUY	$17.96 - $30.46 $88,919 - $150,807	4,951 Added 34.51%	19,299 $463,000
Q2 2022 Aug 12, 2022	BUY	$10.26 - $23.59 $16,539 - $38,027	1,612 Added 12.66%	14,348 $261,000
Q1 2022 May 16, 2022	BUY	$17.02 - $40.22 $14,739 - $34,830	866 Added 7.3%	12,736 $280,000
Q4 2021 Feb 14, 2022	BUY	$29.5 - $39.5 $11,475 - $15,365	389 Added 3.39%	11,870 $436,000
Q3 2021 Nov 12, 2021	BUY	$29.86 - $39.47 $63,124 - $83,439	2,114 Added 22.57%	11,481 $357,000
Q2 2021 Aug 16, 2021	SELL	$17.99 - $40.02 $19,609 - $43,621	-1,090 Reduced 10.42%	9,367 $297,000
Q1 2021 May 14, 2021	BUY	$16.0 - $24.46 $1,056 - $1,614	66 Added 0.64%	10,457 $231,000
Q4 2020 Feb 12, 2021	BUY	$15.89 - $40.87 $165,112 - $424,680	10,391 New	10,391 $205,000

Others Institutions Holding RAPT

# of Institutions

Shares Held

8.03M

Call Options Held

Put Options Held

View Full List

About RAPT Therapeutics, Inc.

Ticker RAPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,656,600
Market Cap $856M
Description
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that se...

More about RAPT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.

Account